Analytical and clinical validation of PATHWAY Anti-HER-2/neu (4B5) antibody to assess HER2-low status for trastuzumab deruxtecan treatment in breast cancer.
Garrido C, Manoogian M, Ghambire D, Lucas S, Karnoub M, Olson MT, Hicks DG, Tozbikian G, Prat A, Ueno NT, Modi S, Feng W, Pugh J, Hsu C, Tsurutani J, Cameron D, Harbeck N, Fang Q, Khambata-Ford S, Liu X, Inge LJ, Vitazka P.
Garrido C, et al. Among authors: tozbikian g.
Virchows Arch. 2024 Jun;484(6):1005-1014. doi: 10.1007/s00428-023-03671-x. Epub 2023 Oct 20.
Virchows Arch. 2024.
PMID: 37857998
Free PMC article.